CAMBRIDGE, Mass. and HAMBURG, Germany, Sept. 26, 2023 /PRNewswire/ -- Novo Nordisk and Evotec SE, today announced LAB eN² (pronounced Lab ee – en – squared), a translational drug discovery accelerator ...
LAB eN² WILL INVOLVE INSTITUTIONS INCLUDING HARVARD UNIVERSITY, MASS GENERAL BRIGHAM, AND BETH ISRAEL DEACONESS MEDICAL CENTER FOCUS OF THE COLLABORATION IS TO ACCELERATE THE TRANSLATION OF ACADEMIC ...
Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center to be developed within LAB eN² focusing ...
(RTTNews) - Novo Nordisk and Evotec have selected three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin Diabetes Center for development ...
LAB eN², which aims to nurture early research from academic institutions into novel therapeutics, has selected its first three projects to move forward in the program from Boston University, Harvard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback